Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Tetra Bio-Pharma Announces Approval to List on the TSX Venture Exchange! http://bit.ly/2wevpGJ
A Tremendous amount of work by the Tetra team to achieve this accomplishment.
"From Start-Up to Explosive Growth"
TSX V ..CONGRATS LONGS AND TBP !!!!!!
That was from FB
Just an update to shareholders. We completed a full day team meeting with our new CEO. Mr. Fortier opened up the meeting with Tetra's theme going forward:
"From Start-up to Explosive Growth"
As trail blazers in developing Tetra Bio-Pharma as an organization, we all recognized that our strategy is so unique, you could use the term, "disruptors" in what we are setting out to achieve. As shareholders begin to fully realize what we have set-out to build, we are most confident in our future success!
We outlined a clear vision going forward:
The Bio-Pharmaceutical Leader in Cannabis - derived by drug discovery with a clinical program aimed at bringing novel drugs and treatments to patients and the healthcare provider.
Each team member outlined their top 3 key objectives. The science team gave an in-depth presentation on their future plans for the company led by Dr. Chamberland. They are by far way ahead of the pack working on many exciting projects.
We look forward to keeping you updated on our execution as we build Tetra into a global leader in bio-pharmaceutical Cannabis!
Wishing our shareholders an enjoyable weekend.
Anything else need to be said here ? Buy now or cry later $$$$$$ can't wait for this thing to run hard! $$TBP $$TBPMF $$
Further media coverage from the announcement yesterday announcing the cannabis health research chair at UNB.
https://www.google.ca/amp/www.cbc.ca/amp/1.4240450
http://globalnews.ca/video/3658658/unb-establishing-cannabis-health-research-chair-ahead-of-marijuana-legalization
http://atlantic.ctvnews.ca/mobile/video?clipId=1184370
Tetra taking a leadership position in pharmaceutical cannabis!
Yes that was an awesome article. The best part last night I was watching my local news and this also air. The only thing its in french but if you forward to around 3:55 min. it says the same thing about the article from the link you had. The news might change for tomorrow if you don't watch it today.
http://ici.radio-canada.ca/tele/le-telejournal-acadie/2016-2017/
Article from Hubble:
FREDERICTON – The province continues to strengthen its research capacity in the marijuana industry with the University of New Brunswick’s announcing Wednesday that it will create a Health Research Chair in Cannabis, funded by the New Brunswick Health Research Foundation and Tetra Bio-Pharma.
http://huddle.today/unb-creates-1-million-chair-research-use-cannabis-healthcare/
Great spot for loading...don't know that it will "take off" without news. TBP ask in the .80's stacked a little. But they drop a revenue/product PR and I'm pretty sure most of that will disappear. GLTU!!! $TBPMF
$$$$$$ put some money in the bank!!!
Sounds like there going sell all APHRIA products locally ....
Use money to fund ppp01 :)
That's what I'm sayin'! Medical MJ is legal with the right approvals. The trials are only testing what consumption levels are necessary for each RX. They're just trying to prove what doses work, not that mj is safe/unsafe. I hear cha' ching.
heres the pr sounds like there going to sell before trial is over ..
Apr 19, 2017
OTC Disclosure & News Service
Tetra Bio-Pharma & Aphria Announce Plans for the Joint Distribution of Dried Medical Cannabis in the Maritime Provinces & Quebec
OTTAWA, ONTARIO--(Marketwired - April 19, 2017) - Tetra Bio-Pharma Inc. ("Tetra") (CSE:TBP)(CSE:TBP.CN)(OTCQB:GRPOF) and Aphria Inc. ("Aphria") (TSX:APH) (OTCQB:APHQF), announced plans today for the joint distribution of dried medical cannabis in the maritime provinces and Quebec.
Tetra and Aphria will enter into a joint supply agreement, with Aphria supplying dried medical cannabis under its ACMPR license, and Tetra packaging the product using the manufacturing process developed for its in-progress clinical drug trial for PPP001. The formulation and packaging will be completed by Tetra, under its CDSA dealer's licence, at its New Brunswick facility. Based on the success of the venture, Tetra and Aphria may expand into other provinces. The venture is preparing to initiate its commercial operations early summer 2017 with revenues commencing in Tetra's third quarter of 2017 and Aphria's first quarter of 2018.
"This commercial venture is an important decision for Tetra shareholders as it will start generating revenues this summer which will be invested back into developing PPP001 as a prescription pharmaceutical," said Andre Rancourt, CEO of Tetra Bio-Pharma Inc. "Tetra will be accelerating its manufacturing and quality studies as required by the U.S. and Canadian prescription drug and controlled substance regulations. The investment in this research will be offset by sales revenues generated under the ACMPR."
"The commercial venture between Tetra and Aphria will enhance Aphria's brand visibility and distribution of our high-quality medical grade cannabis into the maritime provinces and Quebec, as we look to meet the commercial demand for PPP001," said Vic Neufeld, CEO of Aphria Inc. "As a leading Canadian licensed producer, it was important for us to work with an organization that shares our focus on pharmaceutical-grade quality assurance and control. Tetra's emphasis on developing products driven by patient needs and scientific research and development makes them the perfect partner in this important next step for Aphria."
Tetra and Aphria have invested in the development of its PPP001 drug and will continue to invest to bring PPP001 to market in both Canada and USA as the first prescription drug using dried cannabis. The corporations have developed a high quality dried cannabis product and would like to make it available to physicians under the current ACMPR program. The quality and clinical research studies completed to date would be integrated into a joint Continuing Medical Education program for physicians and pharmacists. Tetra and Aphria have concluded that there is demand for an evidence-based approach in medical cannabis and the two companies intend on using their pharmaceutical approach to help patients. The venture will also be commercializing devices for the inhalation of medical cannabis.
About Tetra Bio-Pharma:
Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(OTCQB:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.
Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.
About Aphria:
Aphria Inc., one of Canada's lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders. We are the first public licenced producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters. For more information, visit www.Aphria.com.
I'm not sure if being in a trial limits there ability to sell to the public. If medical mj is legal in Canada and their product is 100% mj they should be able to sell it. The trials are designed to determine the precise amount of mj per "dose" that is optimal for the condition it is prescribed. In other words, every one else is selling mj for medical, why can't Tetra?
http://tetrabiopharma.com/product/phyto-pain/default.aspx
I think what they mean by launching is having a completed product in package for use during trial. As long as they don't sell it, I'm thinking they could pre-process inventory for sale after they're given the go-ahead. That's my take, but I might be confused too. lol
Tetra Bio-Pharma Announces Results of Voting at Annual Shareholders' Meeting & Provides a Corporate Update
I'm thinking your timeline is pretty close. I hope everyone watching without a position gets in before end of summer. The next year and a half are looking to be one heckuva ride! $TBPMF
same here. I am hoping this will be a big return when the phase3 is out. Holding til next year.
No clue. I'm hoping to be above a dollar after summer. Then next year if they get FDA approval hopefully will see 5$ easy. If not still around 2$ they still have other product they are working on. If they could push that out to the market. To me it's like going to the bank and they lock down my money for 1 year. Instead of a 4%-8% increase it would be more like a 150% to 500% increase. I'm averaging at .69 cents. I'm not even touching these share until next summer for sure.
What do you expect the pps to go to ? i got in at about .20 and have been here since. Not a big investor, just a very very small fish ;)
Hoping the end of Summer but if you look at the long picture will be a lot higher by next year !! This is my stock that I got money in and not even thinking of selling some before 2 years and hopefully will put me debt free for good !!
Stock has been awfully quiet. Any expectations on when we should see some movements?
The stock has been awfully quiet. Any expectations on when we should see some movement?
Here's the link news update!! https://m.facebook.com/tetrabiopharma/posts/1400837866667266
New interview out !!
Funny been watching global arena, was gonna sell off some TBP but hate giving up shares.
Big money is the goal that's why it's my name lol, if you guys are interested in crypto currencies you might want to look into Global Arena Holdings, Good things on the horizon shorter term and longer term, investing in the future gets you "bigmoneyyyyy" hence my name lol
Lol ...... your crazy
I tried, but this is the closest i got.
Change your name to Cookie Monster
They'll find out when it's too late, many of my cookies are in this jar, and they'll be here for time. $$$$$$$$$!
No one listens bro, lol
My trend line says it wants to take me higher!
This stocks is a unicorn ..
Watching this one close for a break above .69
Morning! She's building up steam!
Tetra Bio-Pharma Signs Letter of Intent with Constance Therapeutics
OTTAWA, ONTARIO--(Marketwired - July 19, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announced today it has signed a Letter of Intent (LOI) with Constance Therapeutics, Inc. of San Francisco, California, USA, for the clinical development and commercialization in Canada of its signature standardized, patent-pending, medicinal cannabis extract products.
The AgroTek Health subsidiary of Tetra will work with Constance Therapeutics to bring these products to the Canadian medical marijuana market under a commercial license agreement. "Over the coming months, the corporation will be focusing its energy on generating revenues while becoming an important player in the medical marijuana market," commented Mr. Andre Rancourt, CEO of Tetra. "The products developed by Constance Therapeutics are exactly what the corporation is looking for in terms of novel cannabis products developed for patients. The approach used by Constance Therapeutics is exactly the type of business model that Tetra is implementing to bring medical marijuana products to patients."
"Constance Therapeutics works in conjunction with physicians and medical professionals to provide integrative medicinal options to those suffering from serious conditions, such as cancer, lyme, auto-immune, chronic pain, neurodegenerative diseases, and other out-of-option patients," commented Constance Finley, Founder and CEO of Constance Therapeutics, Inc. She added, "over the years, research demonstrates that cannabinoids including specific terpenes, reduce and inhibit tumor growth in various animal models. Early clinical studies suggest cannabinoids enhance the effects of traditional cancer treatments with radiation therapy and help reduce the size of brain cancers, such as Glioma, compared to controls."
Tetra will enter into a licensing agreement with Constance Therapeutics to perform clinical research on the novel cannabis extract products initially focusing on their use in treating patients with brain cancer. Tetra will work closely with oncologists to evaluate the therapeutic benefit of these products according to pharmaceutical standards.
These products are currently available to patients living in California, USA and are consumed sublingually and through vaporization. As part of its mission to bring effective cannabinoid-based products to cancer patients, Tetra will be working in partnership with Constance Therapeutics to investigate the potential efficacy in a clinical trial.
About Constance Therapeutics:
Constance Therapeutics, Inc. is a manufacturer and licensor of cannabis products designed to enable medical professionals offer their patients a broader array of treatment options. The products fill the gap between traditional pharmaceuticals and commonplace cannabis products through manufacturing protocols using highly controlled, quantitatively-defined and patented processes. The products are third-party tested in the industry's most respected laboratories. Since 2008, the company has employed stringent, science-based processes and standards to ensure the highest quality and consistency. Headquartered in San Francisco, California, Constance Therapeutics' products have historically been accessed exclusively for therapeutic use and could only be purchased by registered California patients, in keeping with Proposition 215, and California Senate Bill 420. For further information, visit: www.constancetherapeutics.com.
About Tetra Bio-Pharma:
Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.
Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.
Source: Tetra Bio-Pharma
The Canadian Securities Exchange ("CSE") has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
edward@tetrabiopharma.com
$he seems very nice ;)
http://constancetherapeutics.com/about/constance-finleys-story.html
Sold my wife's shares @ .75 and then bought some for me.
Might be getting legs soon. $TBPMF
Me too. Might be getting more soon! This thing is going to be epic. $TBPMF
Stock looks great wish I held all my shares :(
Tbpmf added to the US Marijuana Index!
Followers
|
84
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
9426
|
Created
|
01/17/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |